In summary, CRISPR/Cas9 appears to be a versatile and powerful strategy for inducing profound changes within the tumor microenvironment through the strategic manipulation of the PD-1/PD-L1 pathway to induce the genetic modulation of immune cells and amplify the effectiveness of cancer therapies, thus emerging as a potent weapon against chemotherapy resistance. This evidence concerns the gene PDCD1 and neoplasm.